Overcoming Osteoporosis R&D Bottlenecks

Overcoming Osteoporosis R&D Bottlenecks with Multi-Dimensional OVX Models

 Against the backdrop of an actively aging global population, osteoporosis has emerged as a major public health issue worldwide. Its core characteristics include reduced bone mass, deterioration of bone microarchitecture, and increased bone fragility, all of which significantly elevate fracture risk ^[1]. Particularly in postmenopausal women, the imbalance of bone metabolism is more pronounced due to the sudden decline in estrogen levels. Consequently, postmenopausal osteoporosis has become a highly important focus area for drug research and development (Figure 1) ^[2].

In the preclinical stage of drug R&D, it is necessary not only to establish stable and reliable animal models but, more importantly, to rely on a systematic, multidimensional evaluation system. This system must comprehensively assess aspects such as bone mass, bone structure, biomechanical function, and systemic metabolism, thereby enhancing the clinical translational value of the research findings. Based on this, constructing a complete preclinical efficacy evaluation framework centered on the classic ovariectomy (OVX) model is critical for the development of osteoporosis therapeutics.

Figure 1. Schematic diagram of age-related changes in female bone mass and postmenopausal osteoporosis ^[2]

The Establishment of OVX-Induced Postmenopausal Osteoporosis Model

 The OVX model involves the surgical removal of bilateral ovaries in experimental animals to induce a decline in systemic estrogen levels, thereby establishing a state of bone metabolism disorder driven by endocrine changes. Estrogen deficiency disrupts the balance between bone formation and resorption, leading to increased resorption and suppressed formation, which subsequently triggers continuous bone loss.

Phenotypically, the OVX animal model exhibits a significant decrease in bone mineral density, deterioration of bone microarchitecture, and reduced biomechanical strength. These pathological changes accurately recapitulate the core features of clinical postmenopausal osteoporosis. Given its high degree of pathological reproducibility, excellent stability, and clinical translational relevance, the OVX model has become the most classic and widely used foundational animal model for evaluating the efficacy of anti-osteoporosis drugs and exploring disease mechanisms ^[3].

Bone Mass-Structure-Function: The Core Evaluation System for Bone Quality

 The essence of osteoporosis lies not only in the reduction of bone mass but also in the deterioration of bone architecture and the decline of biomechanical properties. Therefore, in preclinical studies, it is necessary to conduct a comprehensive evaluation across the three dimensions of “bone mass, structure, and function.” WuXi Biology has successfully established the OVX model and achieved a systematic and in-depth evaluation of bone quality in this model:

• Bone mass dimension: Dual-energy X-ray absorptiometry (DEXA) is the most commonly used detection method. Through quantitative analysis of bone mineral density (BMD) of the whole body or specific sites (such as the femur, lumbar vertebrae, etc.), dynamic changes in bone mass post-OVX can be monitored, and the effects of pharmacological interventions can be evaluated (Figure 2A-B). Because its operation is straightforward and highly consistent with clinical detection methods, it has strong clinical translatability.
• Structural dimension: Micro-computed tomography (micro-CT) provides high-resolution three-dimensional imaging analysis capabilities. By reconstructing the trabecular bone structure, it directly displays changes induced by OVX, such as trabecular thinning, microfractures, and structural disorganization. Meanwhile, this technology provides various quantitative parameters, including bone volume fraction, trabecular thickness, and trabecular separation, thereby reflecting changes in bone architecture more comprehensively (Figure 2C).

Figure 2. Multi-dimensional evaluation system for the OVX-induced osteoporosis model. A). Schematic diagram of OVX model establishment and experimental workflow; B). BMD of different bone sites detected by DEXA; C). Bone microstructural parameters analyzed by micro-CT, including bone volume fraction and trabecular-related indices.

• Biomechanical function dimension: Bone biomechanical testing further evaluates the compressive and bending strength of the bone. The three-point bending test can simulate the stress patterns of bones under external forces. By measuring indices such as maximum load, stiffness, and fracture energy, it reflects changes in bone biomechanical properties (Figure 3A-B). These functional data are of great significance for assessing fracture risk and provide a more direct tool for evaluating drug efficacy.

Figure 3. Multi-dimensional evaluation system for the OVX-induced osteoporosis model. A). Evaluation of bone biomechanical properties via the three-point bending test; B). Quantitative analysis of bone biomechanical parameters (maximum load Fm and fracture load Fb).

By integrating DEXA, micro-CT, and biomechanical functional testing into a single evaluation system, a multi-level systematic analysis of “bone mass alterations-microstructural remodeling-biomechanical property changes” can be achieved. This approach not only systematically characterizes the pathological progression of osteoporosis but also enables a more precise capture of the intervention efficacy of drugs at different stages of action. Such a multi-dimensional integrated analysis model significantly improves the accuracy of efficacy evaluations and deepens the clinical translational value of the research findings.

Histology and Bone Remodeling: Mechanistic Analysis at the Microscopic Level

Beyond macroscopic imaging and biomechanical evaluations, histological analysis provides more direct evidence for elucidating the microscopic pathological processes of osteoporosis. By combining various histochemical staining methods with quantitative analysis, the dynamic balance between bone formation and bone resorption can be systematically evaluated at the cellular and tissue levels.

In histological analysis, WuXi Biology utilizes H&E staining to observe overall structural changes in bone tissue, such as sparse trabeculae and expansion of the bone marrow cavity (Figure 4A). TRAP and ALP staining are employed to label osteoclasts and osteoblasts, respectively, thereby evaluating bone resorption and bone formation activities (Figure 4A and 4B). When combined with calcein double fluorescence labeling, parameters such as mineral apposition rate (MAR) and bone formation rate (BFR) can be further quantitatively analyzed to dynamically reflect the bone formation process (Figure 4A-B). In addition, Toluidine Blue and Von Kossa staining provide supplementary evaluations of the bone tissue status from the perspectives of bone matrix structure and mineralized deposition, respectively, establishing a comprehensive histological evaluation system encompassing “cellular activity—matrix structure—functional mineralization.”

Building upon this foundation, WuXi Biology utilizes bone histomorphometry combined with the aforementioned staining results to conduct systematic quantitative evaluations. This includes assessing various functional indices such as osteoblast surface (Ob.S/BS), osteoclast surface (Oc.S/BS), and bone formation rate (BFR/BS), thereby comprehensively tracking the state of bone remodeling (Figure 4A-B).

In summary, the combined application of histology and histomorphometry not only enables the quantitative analysis of the dynamic changes between bone formation and bone resorption but also sensitively captures the regulatory effects of drugs at different stages of bone remodeling. This provides a more systematic and reliable basis for mechanistic studies and potential target validation.

Figure 4. Histological and bone histomorphometric analysis of the OVX model. A). H&E, Calcein, TRAP, Toluidine Blue, and Von Kossa staining used to observe bone tissue structure, osteogenic and osteoclastic activities, and mineralization status; B). Histomorphometric analysis of bone formation-related indices (e.g., MAR, BFR/BS) and osteoclast-related indices (e.g., Oc.S/BS).

Extra-skeletal Phenotypes: Comprehensive Impacts from the Skeleton to the Whole Body

Osteoporosis is not merely an isolated skeletal disease; rather, it is intimately linked to systemic metabolism and multiple tissue systems. First, skeletal strength depends not only on the intrinsic structure and quality of the bone itself but is also closely related to muscle function. The two interact via the “bone-muscle axis,” jointly influencing the body’s motor capabilities and fracture risk. The OVX model is frequently associated with declines in muscle mass and weakened functional capacity. By measuring muscle weight, conducting grip strength tests, and performing muscle histopathological analysis, WuXi Biology has systematically evaluated the intersection between bone and muscle (Figure 5A-D). This dimension is of profound significance for elucidating the increased fracture risk observed in the elderly population. Second, WuXi Biology also observed that at the metabolic level, OVX animals frequently exhibit weight gain and abnormal body fat distribution. These alterations not only reflect the impact of estrogen deficiency on energy metabolism, but also the subsequent changes in lipid metabolism, which may further exacerbate bone metabolism disorders (Figure 6A-B).

Figure 5. Evaluation of extra-skeletal phenotypes in the OVX model: A). Skeletal muscle index analysis; B). H&E staining of the quadriceps muscle; C). Quantitative analysis of muscle fiber cross-sectional area (CSA); D). Grip strength test to evaluate muscle function.

Figure 6. Evaluation of extra-skeletal phenotypes in the OVX model. A). Analysis of body weight change curve over time; B). Body composition analysis, including fat mass and lean mass.

By introducing the aforementioned extra-skeletal evaluation criteria and expanding the comprehensive analysis from the skeletal system to the levels of muscle and systemic metabolism, it not only allows for a more comprehensive deconstruction of the systemic pathogenesis of osteoporosis but also reveals the interactions between different organs. This approach thereby significantly enhances the representativeness and translational value of animal models in preclinical efficacy evaluations.

From Model Evaluation to Drug Development

Based on the aforementioned multi-dimensional evaluation system, the OVX model not only supports the efficacy evaluation of traditional anti-osteoporosis drugs but also provides a vital translational platform for the development of novel targeted therapeutic strategies. For instance, in the realm of traditional drug evaluation, this model can be used to validate the inhibitory effects of bisphosphonates on bone resorption and the restorative effects of estrogen replacement therapy on bone mass. In the field of novel drug R&D, macromolecular drugs such as antibodies and small interfering RNA (siRNA) can also be systematically validated using this model. To minimize species disparities between animal models and humans, the introduction of humanized models (such as hRANKL mice) can enhance clinical relevance and better predict drug efficacy in human populations. This progression from basic models to humanized models helps to improve the clinical translation success rate.

 Conclusion

Given the complex pathology of osteoporosis, preclinical research requires multi-dimensional evaluations rather than single parameters. A comprehensive system assessing bone mass, structure, function, histology, and systemic phenotypes is essential to accurately gauge disease progression and drug efficacy. Pairing the established OVX model with imaging, biomechanics, and systemic analyses enhances data reliability, clarifies mechanisms of action, and significantly boosts clinical translational value. Moving forward, integrating multi-omics and humanized models will further drive osteoporosis research toward greater precision, accelerating the development of innovative therapies.

Figure 7. Reproductive and endocrine disease models of WuXi Biology.

 References

1. Morin SN, Leslie WD, Schousboe JT. Osteoporosis: A Review. JAMA. 2025;334(10):894–
2. https://medhyaherbals.com/bones-menopause-osteoporosis/
3. Satoshi Inoue, Kaoru Fujikawa, Miwako Matsuki-Fukushima, Masanori Nakamura. Effect of ovariectomy induced osteoporosis on metaphysis and diaphysis repair process. Injury. 2021;52(6):1300-1309.